360° UPSC Mains Analysis

Under the Seventh Schedule of the Constitution of India, legislative power over healthcare is divided: 'Public health and sanitation; hospitals and dispensaries' falls under the State List (List II, Entry 6), making states primarily responsible for healthcare delivery. However, 'Drugs and poisons' falls under the Concurrent List (List III, Entry 19), allowing both the Parliament and State Legislatures to regulate pharmaceutical standards, while the Union List (List I, Entry 66) empowers the Centre to coordinate and determine standards in scientific and technical research institutions.

India's reliance on imported active pharmaceutical ingredients (APIs) and advanced biologics for oncology will decrease, improving the trade balance. Indigenous production of mRNA vaccines will enhance India's position as the 'Pharmacy of the World', boosting high-value biopharmaceutical exports to global markets.

The development of personalized mRNA vaccines can significantly reduce India's high Out-of-Pocket Expenditure (OOPE) on health, which stood at 47.1% of Total Health Expenditure in FY20 according to the Economic Survey 2023-24. Over the long term, local manufacturing of advanced biologics will help contain public health spending, which was 1.9% of GDP in FY24, while driving growth in India's bioeconomy, which reached $150 billion in 2023.

The tertiary healthcare sector and the secondary biopharmaceutical industry will experience a major shift from generic drug manufacturing to high-value precision medicine. This transition will stimulate R&D investments in biotechnology, clinical trial infrastructure, and advanced AI-driven diagnostic services.

The growth of the domestic biopharma ecosystem will create high-skilled employment opportunities for scientists, researchers, and bio-informaticians. It will also strengthen supply chains for cold-chain logistics and specialized medical equipment, though high initial treatment costs may temporarily limit consumer accessibility.

Historically, India's public health approach to cancer was shaped by the post-independence Bhore Committee Report (1946), which highlighted the severe lack of specialized medical facilities and recommended establishing dedicated cancer treatment centers. Following this, the Tata Memorial Hospital, established in 1941 in Mumbai, was commissioned as a pioneer national institution for cancer care and research. In the early decades after independence, cancer was primarily viewed as a localized clinical issue rather than a major public health priority, with treatment limited to basic surgery and radiotherapy.

India's structured policy response began with the launch of the National Cancer Control Programme (NCCP) in 1975 to equip premier cancer institutions. The policy shifted in 1984-85 to emphasize primary prevention and early detection, followed by the introduction of the National Cancer Registry Programme (NCRP) by the Indian Council of Medical Research (ICMR) in 1982 to collect systematic epidemiological data. In 2010, the NCCP was integrated into the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS) to provide a comprehensive non-communicable disease framework. More recently, the National Health Policy (NHP) 2017 and the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PM-JAY) launched in 2018 have expanded financial protection for advanced tertiary cancer care, including immunotherapies.

The transition of mRNA technology from a rapid-response platform during the COVID-19 pandemic to a personalized cancer vaccine mirrors how wartime medical innovations, such as the development of nitrogen mustard (the precursor to chemotherapy) during World War II, were later repurposed to revolutionize oncology. Similarly, the global scale-up of mRNA manufacturing infrastructure during the 2020-2023 pandemic has laid the technical and industrial foundation for the rapid, cost-effective production of personalized cancer therapeutics today.

The establishment of the Tata Memorial Hospital in 1941 by the Sir Dorabji Tata Trust, prior to independence, reflected the early nationalist vision of self-reliance in scientific research and advanced healthcare, which was later championed by leaders like Jawaharlal Nehru through the creation of premier scientific institutions.

The availability of mRNA vaccines offers hope and a chance at dignified survival, reducing the physical and emotional trauma associated with traditional chemotherapy. However, the exorbitant cost of such personalized therapies can lead to severe financial distress, forcing families to sell assets or fall into debt traps, thereby stripping them of economic security and dignity.

Under Article 21 of the Constitution of India, the Right to Life has been judicially interpreted to include the Right to Health and access to timely medical treatment (as held in State of Punjab v. Ram Lubhaya Bagga, 1998). Furthermore, Article 47 of the Directive Principles of State Policy (DPSP) mandates the State to improve public health as a primary duty, while Article 12 of the International Covenant on Economic, Social and Cultural Rights (ICESCR) recognizes the right of everyone to the enjoyment of the highest attainable standard of physical and mental health.

As a public health administrator, one would face the ethical conflict of 'Utilitarianism vs. Egalitarianism'—whether to allocate limited public funds to high-cost, cutting-edge personalized treatments (like mRNA vaccines) for a few, or to strengthen basic primary healthcare and preventive screening for the masses. Additionally, there is the dilemma of 'Right to Life vs. Fiscal Constraints,' balancing the moral duty to provide the best possible treatment against severe budgetary limitations.

Cancer disproportionately impacts vulnerable sections like the elderly, who face higher incidence rates, and the Economically Weaker Sections (EWS), who suffer from catastrophic out-of-pocket health expenditures. Women, particularly in rural areas, face delayed diagnoses for cancers like breast and cervical cancer due to socio-cultural barriers, making advanced, personalized therapies like mRNA vaccines practically inaccessible to them.